Stay updated on Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial page.

Latest updates to the Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to reflect a new clinical trial involving Ixazomib for Recurrent Plasma Cell Myeloma, with significant details about the study's objectives and collaborators. The previous trial involving daratumumab has been removed, indicating a shift in focus.SummaryDifference55%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 6, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.2%
- Check38 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of March 6, 2025, and version 2.14.2.SummaryDifference0.2%
- Check59 days agoChange DetectedThe page has updated its date information, adding several new dates in March and April 2025 while removing some previous dates from February 2025.SummaryDifference0.7%
- Check66 days agoChange DetectedThe webpage has updated its date references, removing past dates from December 2024 and adding new dates in February 2025.SummaryDifference0.7%
Stay in the know with updates to Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial page.